H.C. Wainwright has maintained a Buy rating and an $8.00 price target for InflaRx NV (NASDAQ: NASDAQ:IFRX), following the presentation of a post hoc analysis of the Phase 2b SHINE trial at the European Academy of Dermatology and Venereology Congress, which is currently ongoing from September 25-28, 2024.
The SHINE trial explored the efficacy of Gohibic (vilobelimab) in patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition.
Gohibic is a novel intravenously administered anti-C5a monoclonal antibody developed by InflaRx, which has previously received Emergency Use Authorization from the FDA for COVID-19 treatment.
Despite the trial's initial results on June 5, 2019, which showed that Gohibic did not meet its primary endpoint based on the Hidradenitis Suppurativa Clinical Response score at week 16, the new analysis presented at the EADV Congress highlighted significant clinical efficacy endpoints.
The data indicated a substantial placebo-adjusted reduction in draining tunnels, total lesion counts, and the International Hidradenitis Suppurative Score 4.
InflaRx launched Gohibic commercially in the U.S. on June 21, 2023, for critically ill COVID-19 patients. Additionally, a Marketing Authorization Application for Gohibic is under review by the European Committee for Medicinal Products for Human Use for the treatment of SARS-CoV-2 induced septic acute respiratory distress syndrome in adults.
In other recent news, InflaRx N.V. has reported promising results from a Phase 2b study of vilobelimab, an anti-C5a antibody, in treating hidradenitis suppurativa (HS). The findings showcased vilobelimab's efficacy in reducing HS symptoms, with significant reductions in draining tunnels, total lesion count, and the International Hidradenitis Suppurativa Score 4 (IHS4) at 16 weeks. In addition, the company presented encouraging preclinical data on its novel oral C5aR inhibitor, INF904, highlighting its potential as a potent anti-inflammatory agent.
Furthermore, InflaRx's investigational drug, vilobelimab, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2 clinical study aimed at exploring new treatments for acute respiratory distress syndrome (ARDS).
The company also revealed positive data from a post-hoc subgroup analysis of the PANAMO Phase III study, suggesting that vilobelimab, in combination with standard care medications, may significantly decrease mortality rates in critically ill COVID-19 patients.
Moreover, InflaRx has presented preclinical data on INF904 at the European Meeting on Complement in Human Diseases. The data showed INF904's potential as a strong anti-inflammatory agent with favorable pharmacokinetic properties, demonstrating significant inhibition of C5a-induced neutropenia in a hamster model.
InvestingPro Insights
In light of H.C. Wainwright's maintained Buy rating for InflaRx NV (NASDAQ:IFRX), InvestingPro data and tips offer additional context for investors considering the company's stock. As of the last twelve months leading up to Q2 2024, InflaRx has a market cap of approximately $91.27 million and is trading at a price/book ratio of 0.98, which suggests the stock is valued near its book value. However, the company is not without its challenges, as it is currently not profitable, with a negative gross profit margin of -943.71% and an operating income margin of -37,667.35%. Additionally, the stock has experienced a 47.59% decline in price total return over the past year.
Two InvestingPro Tips provide further insights: InflaRx holds more cash than debt on its balance sheet, which can be an indicator of financial stability, yet it is quickly burning through cash, which raises concerns about long-term sustainability. Additionally, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. There are a total of 10 InvestingPro Tips available for InflaRx, offering a more in-depth analysis for potential investors at https://www.investing.com/pro/IFRX.
These data points and tips may help investors weigh the potential risks and rewards associated with InflaRx's stock, particularly in the context of the company's efforts to commercialize treatments for critical health conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.